BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-390@pharmaconomics
DTSTAMP:20260707T050539Z
DTSTART;VALUE=DATE:20260512
DTEND;VALUE=DATE:20260513
SUMMARY:BBIO Phase 2 — encaleret (estimated date)
DESCRIPTION:Phase 2 trial results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) are due ~ May 12\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm\n\nTrack it: https://www.pharmaconomics.com/e/390
URL:https://www.pharmaconomics.com/e/390
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BBIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR